Exploring Individual Variability in Drug-Induced Liver Injury (DILI) Responses through Metabolomic Analysis

Marta Moreno-Torres,Guillermo Quintás,Teresa Martínez-Sena,Ramiro Jover,José V. Castell

DOI: https://doi.org/10.3390/ijms25053003

IF: 5.6

2024-03-06

International Journal of Molecular Sciences

Abstract:Drug-induced liver injury (DILI) is a serious adverse hepatic event presenting diagnostic and prognostic challenges. The clinical categorization of DILI into hepatocellular, cholestatic, or mixed phenotype is based on serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) values; however, this classification may not capture the full spectrum of DILI subtypes. With this aim, we explored the utility of assessing changes in the plasma metabolomic profiles of 79 DILI patients assessed by the RUCAM (Roussel Uclaf Causality Assessment Method) score to better characterize this condition and compare results obtained with the standard clinical characterization. Through the identification of various metabolites in the plasma (including free and conjugated bile acids and glycerophospholipids), and the integration of this information into predictive models, we were able to evaluate the extent of the hepatocellular or cholestatic phenotype and to assign a numeric value with the contribution of each specific DILI sub-phenotype into the patient's general condition. Additionally, our results showed that metabolomic analysis enabled the monitoring of DILI variability responses to the same drug, the transitions between sub-phenotypes during disease progression, and identified a spectrum of residual DILI metabolic features, which can be overlooked using standard clinical diagnosis during patient follow-up.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

This paper aims to address the challenges in the diagnosis and phenotypic classification of drug-induced liver injury (DILI). Specifically, the study attempts to explore individual responses to DILI through metabolomics analysis, with the goal of obtaining more precise results than traditional clinical classifications.

Currently, DILI is primarily classified based on serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) values, categorizing it into hepatocellular, cholestatic, or mixed types. However, this classification method may not fully capture the various subtypes of DILI. Therefore, researchers used a metabolomics approach to analyze plasma samples from 79 DILI patients, aiming to better characterize these patients' conditions and compare the results with traditional clinical classifications.

By detecting various metabolites in the plasma (including free and conjugated bile acids and glycerophospholipids), and integrating this information into predictive models, the study was able to assess the extent of hepatocellular or cholestatic DILI and quantify the contribution of each specific DILI subtype to the overall condition of the patients. Additionally, metabolomics analysis revealed variations in DILI caused by the same drug among different individuals, monitored the transitions between subtypes during disease progression, and identified some residual DILI metabolic features that might be overlooked in standard clinical diagnoses.

In summary, this study utilizes metabolomics technology to reveal the complexity and individual variability of DILI, providing new insights for further understanding DILI and helping to improve its diagnosis and management.